810 related articles for article (PubMed ID: 7525077)
1. Angiostatin: a novel angiogenesis inhibitor that mediates the suppression of metastases by a Lewis lung carcinoma.
O'Reilly MS; Holmgren L; Shing Y; Chen C; Rosenthal RA; Moses M; Lane WS; Cao Y; Sage EH; Folkman J
Cell; 1994 Oct; 79(2):315-28. PubMed ID: 7525077
[TBL] [Abstract][Full Text] [Related]
2. Angiostatin: an endogenous inhibitor of angiogenesis and of tumor growth.
O'Reilly MS
EXS; 1997; 79():273-94. PubMed ID: 9002223
[TBL] [Abstract][Full Text] [Related]
3. A recombinant human angiostatin protein inhibits experimental primary and metastatic cancer.
Sim BK; O'Reilly MS; Liang H; Fortier AH; He W; Madsen JW; Lapcevich R; Nacy CA
Cancer Res; 1997 Apr; 57(7):1329-34. PubMed ID: 9102221
[TBL] [Abstract][Full Text] [Related]
4. p22 is a novel plasminogen fragment with antiangiogenic activity.
Kwon M; Yoon CS; Fitzpatrick S; Kassam G; Graham KS; Young MK; Waisman DM
Biochemistry; 2001 Nov; 40(44):13246-53. PubMed ID: 11683633
[TBL] [Abstract][Full Text] [Related]
5. Suppression of tumor growth with recombinant murine angiostatin.
Wu Z; O'Reilly MS; Folkman J; Shing Y
Biochem Biophys Res Commun; 1997 Jul; 236(3):651-4. PubMed ID: 9245707
[TBL] [Abstract][Full Text] [Related]
6. Angiostatin induces and sustains dormancy of human primary tumors in mice.
O'Reilly MS; Holmgren L; Chen C; Folkman J
Nat Med; 1996 Jun; 2(6):689-92. PubMed ID: 8640562
[TBL] [Abstract][Full Text] [Related]
7. Radiation therapy to a primary tumor accelerates metastatic growth in mice.
Camphausen K; Moses MA; Beecken WD; Khan MK; Folkman J; O'Reilly MS
Cancer Res; 2001 Mar; 61(5):2207-11. PubMed ID: 11280788
[TBL] [Abstract][Full Text] [Related]
8. Regulation of angiostatin production by matrix metalloproteinase-2 in a model of concomitant resistance.
O'Reilly MS; Wiederschain D; Stetler-Stevenson WG; Folkman J; Moses MA
J Biol Chem; 1999 Oct; 274(41):29568-71. PubMed ID: 10506224
[TBL] [Abstract][Full Text] [Related]
9. Angiostatin potentiates cyclophosphamide treatment of metastatic disease.
Mauceri HJ; Seetharam S; Beckett MA; Schumm LP; Koons A; Gupta VK; Park JO; Manan A; Lee JY; Montag AG; Kufe DW; Weichselbaum RR
Cancer Chemother Pharmacol; 2002 Nov; 50(5):412-8. PubMed ID: 12439600
[TBL] [Abstract][Full Text] [Related]
10. The influence of tumour resection on angiostatin levels and tumour growth--an experimental study in tumour-bearing mice.
Li TS; Kaneda Y; Ueda K; Hamano K; Zempo N; Esato K
Eur J Cancer; 2001 Nov; 37(17):2283-8. PubMed ID: 11677119
[TBL] [Abstract][Full Text] [Related]
11. The mechanism of cancer-mediated conversion of plasminogen to the angiogenesis inhibitor angiostatin.
Gately S; Twardowski P; Stack MS; Cundiff DL; Grella D; Castellino FJ; Enghild J; Kwaan HC; Lee F; Kramer RA; Volpert O; Bouck N; Soff GA
Proc Natl Acad Sci U S A; 1997 Sep; 94(20):10868-72. PubMed ID: 9380726
[TBL] [Abstract][Full Text] [Related]
12. Expression of angiostatin cDNA in a murine fibrosarcoma suppresses primary tumor growth and produces long-term dormancy of metastases.
Cao Y; O'Reilly MS; Marshall B; Flynn E; Ji RW; Folkman J
J Clin Invest; 1998 Mar; 101(5):1055-63. PubMed ID: 9486976
[TBL] [Abstract][Full Text] [Related]
13. Angiostatin inhibits endothelial and melanoma cellular invasion by blocking matrix-enhanced plasminogen activation.
Stack MS; Gately S; Bafetti LM; Enghild JJ; Soff GA
Biochem J; 1999 May; 340 ( Pt 1)(Pt 1):77-84. PubMed ID: 10229661
[TBL] [Abstract][Full Text] [Related]
14. The tumor-suppressing activity of angiostatin protein resides within kringles 1 to 3.
MacDonald NJ; Murad AC; Fogler WE; Lu Y; Sim BK
Biochem Biophys Res Commun; 1999 Oct; 264(2):469-77. PubMed ID: 10529387
[TBL] [Abstract][Full Text] [Related]
15. Kringle domains of human angiostatin. Characterization of the anti-proliferative activity on endothelial cells.
Cao Y; Ji RW; Davidson D; Schaller J; Marti D; Söhndel S; McCance SG; O'Reilly MS; Llinás M; Folkman J
J Biol Chem; 1996 Nov; 271(46):29461-7. PubMed ID: 8910613
[TBL] [Abstract][Full Text] [Related]
16. Combined effects of angiostatin and ionizing radiation in antitumour therapy.
Mauceri HJ; Hanna NN; Beckett MA; Gorski DH; Staba MJ; Stellato KA; Bigelow K; Heimann R; Gately S; Dhanabal M; Soff GA; Sukhatme VP; Kufe DW; Weichselbaum RR
Nature; 1998 Jul; 394(6690):287-91. PubMed ID: 9685160
[TBL] [Abstract][Full Text] [Related]
17. Angiostatin: a circulating endothelial cell inhibitor that suppresses angiogenesis and tumor growth.
O'Reilly MS; Holmgren L; Shing Y; Chen C; Rosenthal RA; Cao Y; Moses M; Lane WS; Sage EH; Folkman J
Cold Spring Harb Symp Quant Biol; 1994; 59():471-82. PubMed ID: 7587101
[No Abstract] [Full Text] [Related]
18. Kringle 5 of plasminogen is a novel inhibitor of endothelial cell growth.
Cao Y; Chen A; An SS; Ji RW; Davidson D; Llinás M
J Biol Chem; 1997 Sep; 272(36):22924-8. PubMed ID: 9278456
[TBL] [Abstract][Full Text] [Related]
19. Selective inhibition by kringle 5 of human plasminogen on endothelial cell migration, an important process in angiogenesis.
Ji WR; Barrientos LG; Llinás M; Gray H; Villarreal X; DeFord ME; Castellino FJ; Kramer RA; Trail PA
Biochem Biophys Res Commun; 1998 Jun; 247(2):414-9. PubMed ID: 9642142
[TBL] [Abstract][Full Text] [Related]
20. The therapeutic efficacy of angiostatin against weakly- and highly-immunogenic 3LL tumors.
Li M; Huang X; Zhu Z; Zhao Q; Wong M; Gorelik E
In Vivo; 2002; 16(6):577-82. PubMed ID: 12494903
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
